title: [Waldenström's macroglobulinemia. Current developments in diagnostics and therapy].
abstract: Waldenström's macroglobulinemia (WM) is a rare subclass of the group of indolent B-cell lymphomas representing only 1-2 % of all hematological neoplasms. Genetic characterization of the disease allows a subdivision of WM into genotypes. The combination of rituximab and chemotherapy is still the backbone of treatment. The proteasome inhibitor bortezomib is another effective treatment option. The newly introduced oral Bruton's tyrosine kinase inhibitor ibrutinib provides an effective chemotherapy-free therapy for WM.
authors.affiliation: Klinik für Innere Medizin III, Universitätsklinikum Ulm, Ulm, Deutschland.
authors.forename: A
authors.initials: A
authors.lastname: Grunenberg
authors.affiliation: Klinik für Innere Medizin III, Universitätsklinikum Ulm, Ulm, Deutschland. christian.buske@uni-ulm.de.|Comprehensive Cancer Center Ulm, Institut für experimentelle Tumorforschung, Universitätsklinikum Ulm, Ulm, Deutschland. christian.buske@uni-ulm.de.
authors.forename: C
authors.initials: C
authors.lastname: Buske
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy / Q000379:methods; D019317:Evidence-Based Medicine; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007167:Immunotherapy / Q000379:methods*; D058990:Molecular Targeted Therapy / Q000379:methods*; D000069283:Rituximab / Q000627:therapeutic use*; D016896:Treatment Outcome; D008258:Waldenstrom Macroglobulinemia / Q000175:diagnosis* / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D000069283:Rituximab
keywords: Bortezomib; Ibrutinib; MYD88 protein; Rituximab; Waldenstrom macroglobulinemia; chemotherapy
references.citation: Bone Marrow Transplant. 2012 Sep;47(9):1147-53
references.pmid: 21874060
references.citation: Blood. 2013 Aug 15;122(7):1222-32
references.pmid: 23836557
references.citation: N Engl J Med. 2014 Mar 13;370(11):1008-18
references.pmid: 24450858
references.citation: Leukemia. 2013 Apr;27(4):762-72
references.pmid: 23385376
references.citation: Blood. 2014 May 1;123(18):2791-6
references.pmid: 24553177
references.citation: Br J Haematol. 2011 May;153(3):309-17
references.pmid: 21385173
references.citation: N Engl J Med. 2012 Aug 30;367(9):826-33
references.pmid: 22931316
references.citation: N Engl J Med. 2014 Mar 20;370(12):1101-10
references.pmid: 24401022
references.citation: J Clin Oncol. 2007 Aug 1;25(22):3344-9
references.pmid: 17577016
references.citation: Br J Haematol. 2011 Aug;154(3):357-62
references.pmid: 21615385
references.citation: Ann Oncol. 2013 Oct;24 Suppl 6:vi155-9
references.pmid: 24078658
references.citation: Blood. 2014 Jul 24;124(4):468-9
references.pmid: 25061164
references.citation: Blood. 2015 Aug 6;126(6):721-32
references.pmid: 26002963
references.citation: Lancet. 2013 Apr 6;381(9873):1203-10
references.pmid: 23433739
references.citation: N Engl J Med. 2015 Apr 9;372(15):1430-40
references.pmid: 25853747
references.citation: Cancer. 2012 Jan 15;118(2):434-43
references.pmid: 21732338
references.citation: Curr Oncol Rep. 2013 Oct;15(5):450-6
references.pmid: 23901022
references.citation: J Clin Oncol. 2010 Mar 10;28(8):1422-8
references.pmid: 20142586